Literature DB >> 2747892

High-dose contrast-enhanced computed tomography (CECT) with iopamidol in the detection of cerebral metastases. Tolerance of the contrast agent.

M Leonardi1, A Lavaroni, E Biasizzo, G Fabris, T Penco, F Zappoli.   

Abstract

Intravenously administered iodinated contrast media have been demonstrated, since early experience with computed tomography of the brain, to improve clinical value of the procedure for detecting intracranial lesions. There is no universal agreement about the amount and the method of administration of the contrast medium. Many authors maintain that the use of large doses gives better results for the diagnosis of tumors and metastases. The purpose of this paper is to evaluate the tolerance of iopamidol administered by rapid intravenous infusion in a large number of patients undergoing contrast enhanced computed tomography to detect brain metastases. The authors examined 969 consecutive adult patients suffering from lung cancer, brain metastases have been detected in 17% of cases. Adverse reactions to contrast media occurred in 3 patients. Non ionic contrast media are recommended in this diagnostic procedure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2747892     DOI: 10.1007/bf00698843

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  29 in total

1.  An approach to contrast enhancement in computed tomography of the brain.

Authors:  R A Kramer; G P Janetos; G Peristein
Journal:  Radiology       Date:  1975-09       Impact factor: 11.105

2.  Convulsions: a complication of contrast enhancement in computerized tomography.

Authors:  J C LoZito
Journal:  Arch Neurol       Date:  1977-10

3.  Iopamidol 300-induced epilepsy: intensive treatment and pathogenic hypothesis.

Authors:  E Carchietti; M Baldassarre; T Penco; M Leonardi
Journal:  Neuroradiology       Date:  1988       Impact factor: 2.804

4.  Acute reactions to urographic contrast medium: incidence, clinical characteristics and relationship to history of hypersensitivity states.

Authors:  D M Witten; F D Hirsch; G W Hartman
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1973-12

5.  Enhancement with water-soluble contrast media in computed tomography of the brain and abdomen. Survey and present state.

Authors:  I O Skalpe
Journal:  Acta Radiol Suppl       Date:  1983

6.  Neurotoxic complications of contrast computed tomography in children.

Authors:  R H Haslam; D D Cochrane; G M Amundson; R D Johns
Journal:  J Pediatr       Date:  1987-12       Impact factor: 4.406

7.  Comparison of side effects during cerebral computed tomography with a nonionic (iohexol) and an ionic (metrizoate) contrast medium.

Authors:  I O Skalpe; M Hordvik
Journal:  AJNR Am J Neuroradiol       Date:  1983 May-Jun       Impact factor: 3.825

8.  Safety and efficacy of sodium and meglumine ioxaglate (Hexabrix) and Hypaque M60% in contrast-enhanced computed cranial tomographic scanning. A double-blind clinical study.

Authors:  R G Ramsey; L Czervionke; M Dommers; M E James; M S Huckman; E J Russell
Journal:  Invest Radiol       Date:  1987-01       Impact factor: 6.016

9.  The epileptogenicity of neurolept anaesthesia in patients during and after neuroradiological examinations with metrizamide.

Authors:  A Rudehill; E Gordon; A Grepe; L Widén
Journal:  Acta Anaesthesiol Scand       Date:  1983-08       Impact factor: 2.105

10.  Diazepam prophylaxis of contrast media-induced seizures during computed tomography of patients with brain metastases.

Authors:  J J Pagani; L A Hayman; R H Bigelow; H I Libshitz; R A Lepke; S Wallace
Journal:  AJR Am J Roentgenol       Date:  1983-04       Impact factor: 3.959

View more
  2 in total

1.  Contrast medium-assisted stereotactic image-guided radiotherapy using kilovoltage cone-beam computed tomography.

Authors:  Keiichi Nakagawa; Hideomi Yamashita; Hiroshi Igaki; Atsuro Terahara; Kenshiro Shiraishi; Kiyoshi Yoda
Journal:  Radiat Med       Date:  2008-11-22

2.  Neuron-specific enolase as a marker of brain metastasis in patients with small-cell lung carcinoma.

Authors:  M van de Pol; A Twijnstra; G P ten Velde; P P Menheere
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.